Achieve Life Sciences (ACHV) Accumulated Expenses (2012 - 2026)

Achieve Life Sciences has disclosed Accumulated Expenses across 15 years of filings, most recently posting $2.2 million for Q1 2026.

• Quarterly Accumulated Expenses rose 126.35% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 126.35% YoY) and the FY2025 annual result came in at $1.9 million, down 36.54% from the prior year.
• Accumulated Expenses advanced to $2.2 million in Q1 2026, from $1.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $3.0 million in Q4 2024 and troughed at $663000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.6 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Accumulated Expenses tumbled 36.54% — and 2026, when it soared 126.35%.
• Tracing ACHV's Accumulated Expenses over 5 years: stood at $1.7 million in 2022, then soared by 37.72% to $2.3 million in 2023, then soared by 30.98% to $3.0 million in 2024, then plunged by 36.54% to $1.9 million in 2025, then increased by 13.59% to $2.2 million in 2026.
• Business Quant data shows ACHV's Accumulated Expenses at $2.2 million in Q1 2026, $1.9 million in Q4 2025, and $2.4 million in Q3 2025.